IP Library › Patent Application 11273871
Patent Application
App. No. 11/273,871

Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/273,871
Abstract

Combinations of hydrophilic and hydrophobic entities in a biodegradable sustained release implant are shown to modulate each other's rate of release. Formulations of a therapeutically active agent and modulator provide substantially constant rate of release for an extended period of time.

Claims (22)

1 - 9 . (canceled)

10 . A method for treating uveitis comprising placing at least one implant in the vitreal chamber of a patient's eye afflicted with uveitis, the at least one implant comprising a matrix and an anti-inflammatory agent.

11 . The method of claim 10 wherein the at least one implant is configured to release the anti-inflammatory agent in the vitreous of the eye over a period of at least three days.

12 . The method of claim 10 wherein the at least one implant is configured to release the anti-inflammatory agent over a period of about 4 to 6 weeks in the vitreous of the eye.

13 . The method of claim 10 wherein the matrix comprises a polymeric material.

14 . The method of claim 10 wherein the matrix is biodegradable.

15 . The method of claim 10 wherein the matrix comprises a biodegradable polymeric material.

16 . The method of claim 10 wherein the at least one implant includes no release modifier.

17 . The method of claim 10 wherein the placing step comprises implanting the at least one implant directly in the vitreous of the eye.

18 . The method of claim 10 wherein the at least one implant is extruded.

19 . The method of claim 10 wherein the at least one implant is an extruded filament.

20 . The method of claim 10 wherein the anti-inflammatory agent is a steroid.

21 . The method of claim 10 wherein the anti-inflammatory agent is a corticosteroid.

22 . The method of claim 10 wherein the anti-inflammatory agent is selected from the group consisting of dexamethasone, hydrocortisone, cortisone, prenisolone, prenisone, progesterone-like compounds, medrysone and fluorometholone.

23 . The method of claim 10 wherein the anti-inflammatory agent is dexamethasone.

24 . The method of claim 10 wherein the matrix comprises a polylactic acid polyglycolic acid (PLGA) copolymer.

25 . The method of claim 20 wherein the matrix comprises a polylactic acid polyglycolic acid (PLGA) copolymer.

26 . The method of claim 21 wherein the matrix comprises a polylactic acid polyglycolic acid (PLGA) copolymer.

27 . The method of claim 22 wherein the matrix comprises a polylactic acid polyglycolic acid (PLGA) copolymer.

28 . The method of claim 23 wherein the matrix comprises a polylactic acid polyglycolic acid (PLGA) copolymer.

29 . The method of claim 10 wherein the anti-inflammatory agent makes up between about 1% and about 80% by weight of the at least one implant.

30 . A method for treating uveitis comprising placing an extruded filament implant into the vitreal chamber of a patient's eye afflicted with uveitis, the implant comprising a PLGA copolymer and an anti-inflammatory corticosteroid, wherein the implant is configured to release the anti-inflammatory agent over a period of up to about 6 weeks.